Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy.

@article{Yhim2012MatchedpairAC,
  title={Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy.},
  author={Ho-Young Yhim and Jin Seok Kim and Hye Jin Kang and Seok Jin Kim and Won Seog Kim and Chul Won Choi and Hyeon Seok Eom and Jeong-A Kim and Jae Hoon Lee and Jong Ho Won and Hyeok Shim and Jooryung Huh and Dae-ho Lee and Cheolwon Suh and J Kwak},
  journal={International journal of cancer},
  year={2012},
  volume={131 1},
  pages={
          235-43
        }
}
Primary breast diffuse large B-cell lymphoma (DLBCL) is an extremely rare presentation of non-Hodgkin's lymphoma that has been associated with poorer clinical outcomes compared with nodal DLBCL in the pre-rituximab era. The aim of this study was to investigate the impact of rituximab on clinical outcomes in patients with primary breast DLBCL. Data from 25 female patients with primary breast DLBCL receiving rituximab plus chemotherapy were matched to 75 female patients (1:3) with nodal DLBCL by… CONTINUE READING